Key Trends and Characteristics of the Cytostatic Industry
1 ONCOLOGY INDUSTRY ANALYSIS
1.1 Key trends and characteristics of Cytostatic industry
• high growth rate – higher propotion of the global pharma market in the years to come
• one of the fastest growing and most profitable therapeutic areas of the next few decades
• shift from accute cancer treatment to chronic disease management and prevention
• more and more biotech companies enter the market – connections with pharma to help through the maze of regulatory processes and clinical development
• patient advocacy programs
1.2 Opportunities of L therapeutic class to pharma companies
• large unmet medical needs - o 5 mil new cases every year, second leading causes of dead o according to WHO 10 mil cases in 2000 and expected to grow to 14,7 mil within next 20 years
• low volume, high price
• small marketing resources (hospitals, tenders)
• significant off-label usage
• favoruable reimbursment environment – global healthcare expenditure for cancer exceed $110 bn
1.3 Oncology industry
The attraction of the cancer market to the pharmaceutical and biotechnology industry is as follows by Global Equity Research (Cancer, New Frontiers, UBS Warburg, October 2001):
large unmet medical need
low volume, high price
small marketing resource
small R&D expenditure
significant off-label usage
favourable reimbursement environment
Global healthcare expenditures for cancer exceed $110 billion annually (for that round about 16 % get on anticancer pharmaceuticals), and every major pharma company is wing for position in that lucrative market, according to a report by C.J. Sylvester, analyst for UBS Warburg. With the growth rate of over-65 populations outpacing other demographics, the ontology market can only escalate, especially as industry shifts focus from acute-care to chronic- disease management.
Cancer will be the most critical and costly healthcare-management issue of the future, making the oncology market one of the
1.1 Key trends and characteristics of Cytostatic industry
• high growth rate – higher propotion of the global pharma market in the years to come
• one of the fastest growing and most profitable therapeutic areas of the next few decades
• shift from accute cancer treatment to chronic disease management and prevention
• more and more biotech companies enter the market – connections with pharma to help through the maze of regulatory processes and clinical development
• patient advocacy programs
1.2 Opportunities of L therapeutic class to pharma companies
• large unmet medical needs - o 5 mil new cases every year, second leading causes of dead o according to WHO 10 mil cases in 2000 and expected to grow to 14,7 mil within next 20 years
• low volume, high price
• small marketing resources (hospitals, tenders)
• significant off-label usage
• favoruable reimbursment environment – global healthcare expenditure for cancer exceed $110 bn
1.3 Oncology industry
The attraction of the cancer market to the pharmaceutical and biotechnology industry is as follows by Global Equity Research (Cancer, New Frontiers, UBS Warburg, October 2001):
large unmet medical need
low volume, high price
small marketing resource
small R&D expenditure
significant off-label usage
favourable reimbursement environment
Global healthcare expenditures for cancer exceed $110 billion annually (for that round about 16 % get on anticancer pharmaceuticals), and every major pharma company is wing for position in that lucrative market, according to a report by C.J. Sylvester, analyst for UBS Warburg. With the growth rate of over-65 populations outpacing other demographics, the ontology market can only escalate, especially as industry shifts focus from acute-care to chronic- disease management.
Cancer will be the most critical and costly healthcare-management issue of the future, making the oncology market one of the